Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

GSK Begins Detailing Xenical Ahead Of OTC Switch Opportunity

This article was originally published in The Pink Sheet Daily

  • News
  • Andrew Shelton

Executive Summary

GlaxoSmithKline's Consumer Healthcare division will detail the weight-loss therapy, focusing on diabetes risk reduction data recently added to labeling. Xenical was last detailed by Roche in November 2003. The Rx-to-OTC application is planned for mid-year.

You may also be interested in...



Sosei Considers Future Of Fibromyalgia Candidate AD 337 After Failed Phase II Trial

Tokyo-based Sosei Group is not ready to give up on its fibromyalgia candidate AD 337 after a Phase II study failed to meet its primary endpoint, the firm announced Sept. 18

Sosei Considers Future Of Fibromyalgia Candidate AD 337 After Failed Phase II Trial

Firm says drug could have some potential in treatment of fibromyalgia syndrome.

Sosei Considers Future Of Fibromyalgia Candidate AD 337 After Failed Phase II Trial

Firm says drug could have some potential in treatment of fibromyalgia syndrome.
Table

View full table

Related Content

Pink Sheet Pink Sheet Pink Sheet Pink Sheet

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

PS061970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By